Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AB102 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SAD Part | EXPERIMENTAL | Escalating single oral doses of AB102 will be given to participants |
| SAD Part Placebo | EXPERIMENTAL | Escalating single oral doses of placebo will be given to participants |
| MAD Part | PLACEBO_COMPARATOR | Escalating multiple oral doses of AB102 will be given to participants |
| MAD Part Placebo | PLACEBO_COMPARATOR | Escalating multiple oral doses of placebo will be given to participants |
| Name | Type | Description |
|---|---|---|
| AB102 | DRUG | Administered orally as specified in the treatment arm |
| Placebo | OTHER | Administered orally as specified in the treatment arm |
Inclusion Criteria: * Understands the study procedures in the Informed Consent Form and is willing and able to comply with the protocol. * BMI: 19.0 to 30.0 kg/m2, inclusive, at screening. * All prescribed medication must have been stopped at least 30 days prior to admission to the clinical site. A...
AB102 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a trial evaluating its safety, tolerability, and pharmacokinetics. AB102 is not approved for any indication and remains under investigation.
AB102 targets MRGPRX2, a receptor involved in various physiological processes. By modulating this receptor, AB102 may have therapeutic potential, though its exact clinical application is still being explored in early-stage trials.
AB102 is being developed by Arcus Biosciences, Inc., a biopharmaceutical company traded on the NYSE under the ticker RCUS. The company is conducting a Phase 1 clinical trial to evaluate the drug's safety and pharmacokinetics in healthy participants.
AB102 is in Phase 1 clinical development. The ongoing trial, NCT07662057, is recruiting participants to assess the drug's safety, tolerability, and pharmacokinetics. As an investigational agent, AB102 has not yet received regulatory approval.
AB102 is being studied in a single Phase 1 trial, NCT07662057, titled 'A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants.' This randomized, double-blind, placebo-controlled trial is recruiting 130 participants in the Netherlands.